Top 5 Papers
#1
Source: Med (Cell Press) | Authors: Petrelli F, … Ghidini M (senior); ASST Bergamo Ovest & Fondazione IRCCS Ca' Granda Policlinico, Milan | Published: June 29, 2026
Score: 8/20 — Base 5 (Med, Cell Press — other peer-reviewed journal) + network meta-analysis (+2) + biomarker-guided / precision sequencing (+1) = 8
Biliary tract cancer has gone from a therapeutic desert to a crowded, genotype-driven landscape in barely five years, and this Cell Press synthesis is the first to put the whole field into a single sequencing framework. Pooling 32 trials in a network meta-analysis, the authors confirm chemoimmunotherapy — durvalumab plus gemcitabine/cisplatin from TOPAZ-1 (median OS 12.9 vs 11.3 months, HR 0.76) and the pembrolizumab regimen from KEYNOTE-966 — as the first-line standard, then map the expanding second-line targeted menu. The headline for practice is molecular: genotype-matched therapy reduced progression risk versus FOLFOX with a striking HR of 0.44, FGFR2-fusion inhibitors delivered response rates of 35–42% with median PFS of 6.9–9.0 months post-platinum, and ivosidenib in IDH1-mutant disease cut progression risk (PFS HR 0.37). The authors' central argument is one of implementation, not just efficacy — the survival gains only materialize if comprehensive genomic profiling is done early and worldwide, before patients are too sick to sequence. For anyone treating cholangiocarcinoma, this is a usable roadmap for ordering FGFR2, IDH1, HER2, BRAF and MSI testing up front and slotting the matched drug into the right line.
Post angle: Cholangiocarcinoma is now a genotype-driven disease — if you profile early enough. A 32-trial network meta-analysis (Med) confirms durvalumab+GemCis as 1L (TOPAZ-1 HR 0.76) and shows genotype-matched therapy cuts progression risk vs FOLFOX (HR 0.44), with FGFR2 inhibitors ORR 35–42% and ivosidenib IDH1 PFS HR 0.37. The message: send comprehensive genomic profiling on day one. #Cholangiocarcinoma #GIOnc #PrecisionMedicine
#2
Source: Journal of Clinical Oncology | Authors: Temperley HC & Kelly ME; Trinity St James's Cancer Institute, Dublin | Published: June 29, 2026
Score: 8/20 — Base 8 (JCO) — narrative review, no study-type or survival bonus; GI cancer a central theme = 8
GLP-1 receptor agonists have reshaped how oncologists think about obesity and metabolic health, and this JCO review asks the natural next question: what might they mean for cancer itself? The authors pull together the epidemiologic and mechanistic threads linking GLP-1RAs — semaglutide, tirzepatide and their class — to lower risk of obesity-associated malignancies, several of which are gastrointestinal (colorectal, pancreatic, esophageal, gastric and hepatobiliary). Beyond weight loss, they map plausible antitumor mechanisms: improved insulin signaling and reduced hyperinsulinemia, dampened chronic inflammation, effects on angiogenesis, and immune modulation. They also flag a practical, near-term role — using these agents for metabolic optimization in the perioperative and neoadjuvant window, where fitness and body composition influence surgical and treatment outcomes. This is a review, not new trial data, and the authors are appropriately cautious about causality and about open questions on muscle loss, timing and drug–treatment interactions. But it is a useful state-of-the-field for a topic patients are already asking about, and a reminder that metabolic co-management is edging from the endocrinology clinic into the oncology conversation.
Post angle: Patients are already asking whether GLP-1 drugs matter for their cancer. A new JCO review maps the evidence: GLP-1 receptor agonists are linked to lower risk of obesity-related cancers — many of them GI — with mechanisms spanning insulin signaling, inflammation, angiogenesis and immunity, plus a possible role in perioperative metabolic optimization. Still hypothesis-generating, but the metabolic-oncology conversation has arrived. #GIOnc #GLP1 #Obesity #CRC
#3
Source: Journal of Gastrointestinal Cancer | Authors: Mareedu T, Iftikhar A, et al.; multicenter (India / NIH / University of Arizona) | Published: June 30, 2026
Score: 7/20 — Base 5 (Journal of Gastrointestinal Cancer — other peer-reviewed journal) + meta-analysis (+2) = 7
How best to treat resectable esophageal and junctional cancer before surgery — chemoradiotherapy or chemotherapy alone — remains one of the most actively debated questions in upper-GI oncology, sharpened by recent trials pulling in different directions. This systematic review and meta-analysis pooled 8 randomized trials comparing preoperative chemoradiotherapy against perioperative chemotherapy in resectable esophageal/GEJ carcinoma. Chemoradiotherapy came out ahead on local, pathology-based endpoints: it improved R0 (margin-negative) resection rates (risk ratio 0.94, 95% CI 0.89–0.99) and markedly increased pathologic complete response (RR 0.27, 95% CI 0.13–0.58). Crucially, though, those pathologic gains did not translate into a survival advantage — there was no significant difference in overall survival, progression-free survival, postoperative mortality or severe adverse events between the two strategies. A subgroup signal favored chemoradiotherapy in squamous cell carcinoma. The practical read is nuanced rather than decisive: chemoradiotherapy buys better local clearance and more pCRs, but with current regimens that hasn't moved the survival needle over chemotherapy, and histology may help decide — a reminder to watch how the newer perioperative immunotherapy trials reshape this comparison.
Post angle: CRT or chemo before esophageal surgery? A new 8-RCT meta-analysis (J Gastrointest Cancer): preoperative chemoradiotherapy improves R0 resection (RR 0.94) and pathologic complete response (RR 0.27) vs perioperative chemo — but with no OS or PFS difference. Better local clearance, same survival; a squamous-cell signal favors CRT. Histology and the new IO trials will keep moving this line. #EsophagealCancer #GIOnc
Additional Papers of Interest
-
Journal for ImmunoTherapy of Cancer — in a Phase II pembrolizumab trial across 84 patients with rare tumors (10 cohorts, including GI histologies), a deep-learning analyzer of pre- and on-treatment biopsies found that rising intratumoral lymphocyte density plus falling tumor content tracked with better PFS and OS (combined HR 0.36 for both), positioning AI-quantified TME dynamics as an early on-treatment biomarker of checkpoint-blockade benefit.
-
European Journal of Cancer — this dendrimer-nanoparticle formulation of cabazitaxel (n=89; cohorts in prostate, ovarian and esophago-gastric cancer) was well tolerated with reduced marrow toxicity and showed activity in the esophago-gastric group (ORR 30%, 3/10), a signal worth tracking as reformulated taxanes look for a niche in upper-GI disease.
-
Medicine (Baltimore) — a PRISMA meta-analysis of 21 case-control studies identifies modifiable and non-modifiable drivers of intra-abdominal infection after colorectal cancer surgery (including hypoalbuminemia, prolonged operative time >150 min, perioperative transfusion and anastomotic leak), a useful checklist for perioperative optimization and infection-control planning in the surgical GI patient.
Back to all digests